Isao Sakurada
Mochida Pharmaceutical (Japan)(JP)Pfizer (United States)(US)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Oxidative Organic Chemistry Reactions, Blood Coagulation and Thrombosis Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Atrial Fibrillation Management and Outcomes
Most-Cited Works
- → Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator(2014)51 cited
- → Direct Chlorohydrin and Acetoxy Alcohol Synthesis from Olefins Promoted by a Lewis Acid, Bis(trimethylsilyl) Peroxide and (CH3)3SiX(2000)42 cited
- → Dichlorotin oxide-catalyzed new direct functionalization of olefins: synthesis of trans β-azidohydrins and 1,2-diols(2000)18 cited
- → Development of a novel class of potent and selective FIXa inhibitors(2015)16 cited
- → Development of a novel tricyclic class of potent and selective FIXa inhibitors(2015)16 cited
- → Discovery of (−)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone—A potent NR2B-selective N-methyl d-aspartate (NMDA) antagonist for the treatment of pain(2007)15 cited
- → Discovery of novel and orally active NR2B-selective N-methyl-d-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity(2007)14 cited
- → Structure–activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation(2007)12 cited
- → Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors(2017)11 cited
- → Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates(2017)9 cited